TR200401848T4 - Uzun süreli levodopa ve karbidopa bırakılması içeren kompozisyon. - Google Patents

Uzun süreli levodopa ve karbidopa bırakılması içeren kompozisyon.

Info

Publication number
TR200401848T4
TR200401848T4 TR2004/01848T TR200401848T TR200401848T4 TR 200401848 T4 TR200401848 T4 TR 200401848T4 TR 2004/01848 T TR2004/01848 T TR 2004/01848T TR 200401848 T TR200401848 T TR 200401848T TR 200401848 T4 TR200401848 T4 TR 200401848T4
Authority
TR
Turkey
Prior art keywords
carbidopa
levodopa
composition containing
term release
containing long
Prior art date
Application number
TR2004/01848T
Other languages
English (en)
Inventor
Seth Pawan
Original Assignee
Pharma Pass France S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Pass France S.A.S. filed Critical Pharma Pass France S.A.S.
Publication of TR200401848T4 publication Critical patent/TR200401848T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bulus, terapötik olarak etkili miktarda levodopa ve karbidopa içeren, hidrofilik bir matris içinde dagilmis bir farmasötik kompozisyonla ilgilidir, sözü edilen kompozisyon bir organik asit içerir. Bulus ayrica kompozisyonu hazirlamak için bir islemle ilgilidir, islem; özellikle sivilastirilmis bir yatakta çesitli bilesenlerin granülasyonu ve elde edilen taneciklerin sikistirilmasini içerir.
TR2004/01848T 2001-05-29 2002-05-17 Uzun süreli levodopa ve karbidopa bırakılması içeren kompozisyon. TR200401848T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/866,857 US6531153B2 (en) 2001-05-29 2001-05-29 Composition with sustained release of levodopa and carbidopa

Publications (1)

Publication Number Publication Date
TR200401848T4 true TR200401848T4 (tr) 2004-09-21

Family

ID=25348578

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01848T TR200401848T4 (tr) 2001-05-29 2002-05-17 Uzun süreli levodopa ve karbidopa bırakılması içeren kompozisyon.

Country Status (8)

Country Link
US (1) US6531153B2 (tr)
EP (1) EP1262198B1 (tr)
AT (1) ATE265231T1 (tr)
DE (1) DE60200416T2 (tr)
DK (1) DK1262198T3 (tr)
ES (1) ES2222436T3 (tr)
PT (1) PT1262198E (tr)
TR (1) TR200401848T4 (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
AU2003214551A1 (en) * 2002-04-11 2003-10-20 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
AU2003260200A1 (en) * 2002-09-03 2004-03-29 Universite Libre De Bruxelles Reversible, parallel and multitask cloning method and kit
US20070009596A1 (en) * 2003-05-14 2007-01-11 Bruschi Stefano D L Controlled drug release composition resistant to in vivo mechanic stress
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
RU2440100C2 (ru) * 2005-03-28 2012-01-20 Орексо Аб Новые фармацевтические композиции, полезные в лечении болезни паркинсона
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008030830A2 (en) * 2006-09-08 2008-03-13 Drugtech Corporation Sustained-release composition and method of use thereof
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ATE549438T1 (de) * 2007-01-10 2012-03-15 Crystal Systems Corp Vorrichtung zum tiegelfreien zonenschmelzen
US20090155369A1 (en) * 2007-12-13 2009-06-18 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
AU2014202306B2 (en) * 2007-12-28 2016-09-08 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
AU2008343787B2 (en) 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
WO2010019915A1 (en) 2008-08-15 2010-02-18 Depomed Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CA3031412C (en) 2017-06-16 2020-08-11 Kashiv Pharma Llc Gastroretentive dosage forms for sustained drug delivery
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
EP3824881B1 (en) 2018-06-18 2022-02-16 Amneal Complex Products Research LLC Extended release compositions comprising pyridostigmine
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua

Also Published As

Publication number Publication date
PT1262198E (pt) 2004-09-30
ES2222436T3 (es) 2005-02-01
DE60200416T2 (de) 2005-03-03
US20020192290A1 (en) 2002-12-19
EP1262198A1 (en) 2002-12-04
ATE265231T1 (de) 2004-05-15
DE60200416D1 (de) 2004-06-03
DK1262198T3 (da) 2004-08-16
EP1262198B1 (en) 2004-04-28
US6531153B2 (en) 2003-03-11

Similar Documents

Publication Publication Date Title
TR200401848T4 (tr) Uzun süreli levodopa ve karbidopa bırakılması içeren kompozisyon.
BR0110703A (pt) Amida, composição farmacêutica que compreende um composto, compostos, utilização de compostos, processos para o tratamento profilático ou terapêutico de diabetes do tipo ii e para a preparação desses compostos
TR200200688T2 (tr) Doğrudan tablet şeklinde preslenebilen ultra ince asetaminofen terkipleri ve bu terkiplerin üretim prosesi
SE9301489D0 (sv) Veterinary composition
HK1068282A1 (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for usein treatment of ulcerative colitis and crohn's di sease
DK0560092T3 (da) Tabletter, granulater og pellets med højt indholdaf aktivstoffer til højkoncentrerede, faste administreringsformer
IN2014DN07624A (tr)
BRPI0414893A (pt) corpos miméticos de núcleo de articulação mimética de epo humanos, composições, métodos e usos
UA81676C2 (ru) Композиция для лечения инфекций у крупного рогатого скота и свиней
AU1255002A (en) Delayed-release pharmaceutical formulations
FI925787A (fi) Proteolytiska enzymers sackarinderivatinhibitorer
FR2780052B1 (fr) Agglomerats a base de charbon actif leur procede de preparation et leur utilisation comme agents d'adsorption
UY26256A1 (es) Amidas de ácidos carboxílicos, medicamentos que contienen estos compuestos, su utilización y su preparación
TW270085B (tr)
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
BR9809117A (pt) Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
EA200400072A1 (ru) Твердая композиция, содержащая споры непатогенных бактерий рода bacillus
ATE315395T1 (de) Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten
DE3883098D1 (de) Spruehgetrocknete ibuprofen-zusammensetzungen.
TNSN93008A1 (fr) Procede de reduction de la teneur en formaldehyde de formulations microencapsulees
CA2480429A1 (en) Novel therapeutical use of agonist ligands specific to g2a receptor
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
BR0008739A (pt) Composições de liberação controlada debeta-histina
PT1171111E (pt) Granulado com teor elevado de l-carnitina ou de uma alcanoil l-carnitina particularmente adequado para a producao de comprimidos por compressao directa
DE60220551D1 (de) Tabletten mit verzögerter wirkstofffreisetzung enthaltend indapamid